🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10 results for “anakinra” Clear

  1. Anakinra 100mg and Placebo Depo-Medrone

    United Therapeutics Europe Ltd

    Gout

    phase 3 small molecule completed

    1 trial

  2. BENDAMUSTINE , TOCILIZUMAB , SILTUXIMAB , GEMCITABINE , ANAKINRA , Epcoritamab, DIPHENHYDRAMINE , PARACETAMOL , DEXAMETHASONE , RITUXIMAB , OXALIPLATIN , Epcoritamab

    Genmab A/S

    B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  3. METHYLPREDNISOLONE , CellCept 500 mg film-coated tablets, PREDNISONE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL , ANAKINRA , RoActemra 20 mg/mL concentrate for solution for infusion, DEXAMETHASONE , Acasunlimab

    Genmab A/S

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  4. ANAKINRA

    AXIM BIOTECHNOLOGIES, INC.

    Hyperinflammation, Sepsis

    phase 2 small molecule active

    1 trial

  5. ANAKINRA

    Disc Medicine

    Intracerebral haemorrhage

    phase 2 small molecule active

    1 trial

  6. DIPHENHYDRAMINE , ANAKINRA , DEXAMETHASONE , Epcoritamab, SILTUXIMAB , PREDNISOLONE , TOCILIZUMAB , PARACETAMOL , Epcoritamab

    Genmab A/S

    Lymphoma of B-cell origin

    phase 2 small molecule active

    1 trial

  7. Epcoritamab, Epcoritamab, PARACETAMOL , ANAKINRA , LENALIDOMIDE , DEXAMETHASONE , DIPHENHYDRAMINE , SILTUXIMAB , TOCILIZUMAB

    Genmab A/S

    DIFFUSE LARGE B CELL LYMPHOMA

    phase 2 small molecule active

    1 trial

  8. INTERFERON GAMMA , TOCILIZUMAB , DALTEPARIN , HEPARIN , BARICITINIB, FLUDROCORTISONE , HYDROCORTISONE, OCTAPLASLG, solution pour perfusion, BARICITINIB, ANAKINRA , FILGRASTIM

    Pari Pharma GmbH

    Sepsis

    phase 2 small molecule active

    1 trial

  9. SILTUXIMAB , PREDNISOLONE , CYCLOPHOSPHAMIDE , CARBOPLATIN , PARACETAMOL , ETOPOSIDE , VINCRISTINE , LENALIDOMIDE , DIPHENHYDRAMINE , GEMCITABINE , PREDNISONE , OXALIPLATIN , TOCILIZUMAB , Epcoritamab, Epcoritamab, DEXAMETHASONE , DOXORUBICIN , CYTARABINE , RITUXIMAB , IFOSFAMIDE , ANAKINRA , BENDAMUSTINE

    Genmab A/S

    Lymphoma of B-cell origin

    phase 2 small molecule active

    1 trial

  10. TOCILIZUMAB , SECUKINUMAB , ANAKINRA , ADALIMUMAB , RITUXIMAB, USTEKINUMAB

    Pari Pharma GmbH

    Patients displaying a non-classified, severe and resistant inflammatory disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources